Archive

Neovasc Announces Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer™ for Treatment of Refractory Angina

Participating Hospitals in Germany Now Eligible to Negotiate Reimbursement for Reducer Procedure   NASDAQ, TSX: NVCN    VANCOUVER, January 28, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive...

Read More

Updates on Reducer and Tiara Programs will be presented at Advanced Cardiovascular Intervention 2020 Meeting

  NASDAQ, TSX: NVCN Neovasc Provides Corporate Update   Vancouver, BC, January 21, 2020 - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced...

Read More

Neovasc Receives Administrative Acceptance Review Notification for Premarket Approval Application from FDA for the Neovasc Reducer™

  NASDAQ, TSX: NVCN   VANCOUVER, January 15, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced receipt...

Read More

Neovasc Inc. Investor Update

  NASDAQ, TSX: NVCN   VANCOUVER, January 13, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, seeks to provide...

Read More